Emcure Pharmaceuticals IPO GMP

Subscribe for real-time financial insights on Trade Target’s WhatsApp Channels

Emcure Pharmaceuticals Limited, founded in 1981 is an Indian company that develops, manufactures and markets wide range of pharmaceutical products globally.

By September 2023 Emcure was ranked 13th in domestic sales among Indian pharmaceutical companies and held 4th largest market share in its areas of operation. It was also top company in gynecology and HIV antiviral treatments.

In first half of 2023 and entire financial year domestic sales made up over half of Emcure’s revenue. From 2019 to 2023, these sales grew at an annual rate of 10.80%, outpacing overall Indian pharmaceutical market.

Emcure employs 552 scientists across five research facilities in India. By September 2023 they had filed over 1,800 documents worldwide including 204 in the EU and 133 in Canada with 201 granted patents 33 pending patent applications and 102 drug master files submitted.

The company operates 13 manufacturing facilities in India producing variety of pharmaceutical and biopharmaceutical products. Their capabilities include manufacturing pills, liquids, injectables and complex ingredients like chiral molecules, iron molecules, and cytotoxic substances.

Emcure’s marketing and distribution network in India includes over 5,000 field personnel and more than 5,000 stockists supported by 37 carry-and-forward agents, ensuring regular interaction with healthcare providers.

Emcure Pharmaceuticals IPO Overview

Emcure Pharma is launching an IPO worth Rs 1,952.03 crores. This includes a fresh issue of shares valued at Rs 800 crores and an offer for sale of shares worth Rs 1,152.03 crores.

The IPO will be open for subscription from July 3 to July 5, 2024. The share allotment is expected to be finalized on July 8, 2024, and the shares are likely to be listed on the BSE and NSE on July 10, 2024.

The price range for the IPO is set between ₹960 and ₹1008 per share. Satish Mehta and Sunil Mehta promoted the company. Before the IPO, the promoters hold 98.90% of the shares.

Link Intime India Private Ltd. is the registrar for this IPO.

Circle with a bank, dollar coin, and fixed deposit text, with an upward arrow representing high FD interest rates.

Highest FD interest rates: Banks that offer up to 9.1% interest on fixed deposits

India map in Indian flag colors with NavIC label connected to a satellite clipart pointing towards the US map in US flag colors with GPS label.

NavIC vs. GPS: The Battle of Navigation Technologies

A girl on one side of a balance scale, with money, a bottle, and a potli on the other, labeled 'Small Cap Mutual Fund.'

Best Small Cap Mutual Funds for Investment

Let’s look at how Emcure Pharmaceuticals IPO GMP has changed recently.

Emcure Pharma’s IPO has a last grey market premium (GMP) of ₹270 as of June 28th, 2024, at 1:56 PM. With a price band set at ₹1008, the estimated listing price is ₹1278 (the upper price band plus today’s GMP). This suggests an expected gain of 26.79% per share.

Stay tuned with Trade Target for daily updates on Emcure Pharmaceuticals IPO GMP and the expected listing price.

Date: 7– July – 2024
Emcure Pharmaceuticals GMP: ₹390 (38.69%)

Date: 6– July – 2024
Emcure Pharmaceuticals GMP: ₹390 (38.69%)

Date: 5– July – 2024
Emcure Pharmaceuticals GMP: ₹371 (36.81%)

Date: 4– July – 2024
Emcure Pharmaceuticals GMP: ₹335 (33.23%)

Date: 3– July – 2024
Emcure Pharmaceuticals GMP: ₹330 (32.74%)

Date: 2– July – 2024
Emcure Pharmaceuticals GMP: ₹299 (29.66%)

Date: 1– July – 2024
Emcure Pharmaceuticals GMP: ₹285 (28.27%)

Date: 30– June – 2024
Emcure Pharmaceuticals GMP: ₹264 (26.19%)

Date: 29– June – 2024
Emcure Pharmaceuticals GMP: ₹264 (26.19%)

Date: 28– June – 2024
Emcure Pharmaceuticals GMP: ₹271 (26.88%)

How can one apply for Emcure Pharmaceuticals IPO?

Investors interested in the Emcure Pharma IPO can start by bidding for at least 14 shares, with bids in multiples of 14 shares thereafter. Here’s a breakdown of the minimum and maximum investments for retail and high net worth investors (HNI):

Application	Lots	Shares	Amount
Retail (Min)	1	14	₹14,112
Retail (Max)	14	196	₹197,568
S-HNI (Min)	15	210	₹211,680
S-HNI (Max)	70	980	₹987,840
B-HNI (Min)	71	994	₹1,001,952

Emcure Pharmaceuticals IPO Financial

For the financial years ending March 31, 2024, 2023, and 2022, the company’s key financial figures are as follows:

Period Ended	31 Mar 2023	31 Mar 2022	31 Mar 2021
Assets in (₹ Crores)	7,806.16	6,672.53	6,063.47
Revenue (₹ Crores)	6,715.24	6,031.72	5,918.86
PAT (₹ crores)	527.58	561.85	702.56
Total Borrowing (₹ crores)	2,091.94	2,202.42	2,102.19

Emcure Pharmaceuticals Vs Peers

This table highlights the earnings per share and the price-to-earnings ratios of various pharmaceutical companies.

Company	EPS Diluted	P/E(x)
Emcure Pharmaceuticals Limited	27.54	-
Dr. Reddy's Laboratories Limited	335.59	17.93
Cipla Ltd.	51.01	30.1
Alkem Laboratories Ltd	150.19	33.86
Torrent Pharmaceuticals Ltd.	48.94	57.74
Mankind Pharma Limited	47.68	45.3
Abbott India Ltd.	565.28	47.43
J. B. Chemicals & Pharmaceuticals Limited	34.85	50.49

Emcure Pharmaceuticals IPO Quota allocation

Expected Listing Date for Emcure Pharmaceuticals IPO

Happy investing and thank you for reading!

Disclaimer: This website content is only for educational purposes, not investment advice. Before making any investment, it’s important to do your own research and be fully informed. Investing in the stock market includes risks, and you should carefully read the Risk Disclosure documents before proceeding. Please remember that past performance doesn’t guarantee future results, and due to market fluctuations, your investment goals may not always be achieved.